Literature DB >> 2394769

Clinical review 13: Diagnosis and management of Graves' ophthalmopathy.

R S Bahn1, J A Garrity, C A Gorman.   

Abstract

Although Graves ophthalmopathy is a potentially sight threatening and disfiguring condition that can be frightening for the patient to experience, there are effective means of management. At the present time, treatment is based on the relief of excessive intraorbital pressures and is accomplished either by shrinking the orbital contents or by expanding the orbital volume. The most effective treatment modality or combination of modalities is an area of controversy. However, it must be remembered that the approach to management undertaken should be finely tuned to the needs of the particular individual afflicted with the condition. Perhaps with a greater understanding of pathophysiology, more reliable and effective treatments, based on specific pathophysiological mechanisms, may be developed. In addition, tests to reliably predict those patients most likely to progress in their disease might be developed, allowing preventive measures to be taken.

Entities:  

Mesh:

Year:  1990        PMID: 2394769     DOI: 10.1210/jcem-71-3-559

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A.

Authors:  M A Burnstine; S G Elner; V M Elner
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

2.  Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga; R Van der Gaag; M P Mourits; L Koornneef
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

Review 3.  Thyroid associated ophthalmopathy - a review.

Authors:  Ps Mallika; Ak Tan; S Aziz; Sar Syed Alwi; Ms Chong; R Vanitha; G Intan
Journal:  Malays Fam Physician       Date:  2009-04-30

4.  Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 5.  Graves' ophthalmopathy.

Authors:  W E Barrie
Journal:  West J Med       Date:  1993-06

6.  Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.